Aptose Biosciences (NASDAQ:APTO) Receiving Somewhat Positive Media Coverage, Report Finds
News headlines about Aptose Biosciences (NASDAQ:APTO) (TSE:APS) have trended somewhat positive on Monday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aptose Biosciences earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.555550662097 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern’s scoring:
- Aptose Reports Results for the Second Quarter Ended June 30, 2017 (finance.yahoo.com)
- Aptose Biosciences, Inc. (NASDAQ:APTO) Releases Earnings Results, Beats Estimates By $0.07 EPS (americanbankingnews.com)
- Analysts Offer Insights on Healthcare Companies: Aptose Biosciences (NASDAQ: APTO) and HTG Molecular … – Analyst Ratings (analystratings.com)
- Aptose Biosciences Inc. (APTO) registers a price change of -2.52% while Zogenix, Inc. (ZGNX) finishes with a flow of … – Stocks Gallery (stocksgallery.com)
- Prepping for a Big Move? Share Update on Aptose Biosciences Inc … – FLBC News (flbcnews.com)
A number of analysts have recently weighed in on APTO shares. Canaccord Genuity restated a “buy” rating and issued a $7.00 target price on shares of Aptose Biosciences in a report on Friday, May 12th. HC Wainwright started coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They issued a “hold” rating on the stock. ValuEngine upgraded shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. Finally, Rodman & Renshaw started coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They issued a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $7.00.
Aptose Biosciences (NASDAQ APTO) traded up 0.6966% during mid-day trading on Monday, hitting $1.4601. 171,255 shares of the stock were exchanged. The stock’s market cap is $31.76 million. The stock’s 50 day moving average is $1.43 and its 200 day moving average is $1.17. Aptose Biosciences has a 52-week low of $0.78 and a 52-week high of $3.20.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.07. Analysts forecast that Aptose Biosciences will post ($1.04) EPS for the current fiscal year.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.